Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
277.33
-1.84 (-0.66%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
10 Health Care Stocks With Whale Alerts In Today's Session
August 12, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
August 07, 2024
Via
Benzinga
The 3 Best Gene Editing Stocks to Buy in August 2024
August 07, 2024
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.
Via
InvestorPlace
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
August 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
How Is The Market Feeling About Alnylam Pharmaceuticals?
August 06, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today
July 18, 2024
Via
Benzinga
Peering Into Alnylam Pharmaceuticals's Recent Short Interest
July 17, 2024
Via
Benzinga
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
August 06, 2024
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82.
Via
Investor's Business Daily
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?
August 04, 2024
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H....
Via
Benzinga
Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday
August 01, 2024
Via
Benzinga
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
August 01, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Peering Into Alnylam Pharmaceuticals's Recent Short Interest
June 27, 2024
Via
Benzinga
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...
Via
Benzinga
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
July 18, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Stock Is a Blockbuster Biopharma In the Making
July 18, 2024
Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market.
Via
InvestorPlace
35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success.
July 11, 2024
Alnylam Pharmaceuticals stock recently popped and could continue to move higher on Alnylam Pharmaceuticals' cardiovascular drug announcement.
Via
InvestorPlace
7 Cheap Biotech Stocks With Major Upside Potential
July 09, 2024
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.
Via
InvestorPlace
Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?
July 08, 2024
Shares of the world's largest drugmaker offer a dividend yield above 6% at recent prices.
Via
The Motley Fool
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
July 07, 2024
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs.
Via
Benzinga
Topics
ETFs
$100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
July 03, 2024
Via
Benzinga
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
July 01, 2024
June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while utilities lagged.
Via
Benzinga
Topics
ETFs
10 Health Care Stocks With Whale Alerts In Today's Session
July 01, 2024
Via
Benzinga
Rivian Automotive And Carvana Were Among The 10 Biggest Large Cap Gainers Last Week (June 23-June 29): Are These In Your Portfolio?
June 30, 2024
The top 10 large-cap stocks in the last week were RIVN, CUK, FDX, IOT, SUZ, CVNA, FTAI, RDDT, MDB, and ALNY. Many analysts have raised their price forecasts for these stocks.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
June 26, 2024
Via
Benzinga
Nvidia, Affirm Holdings, Carnival Corp, Alnylam Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today
June 24, 2024
On Monday, major U.S. indices showed mixed performance. The Dow Jones Industrial Average closed up by nearly 0.7% at 39,411.21,
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Semiconductor, Nvidia Woes Deepen; Nasdaq 100 Slips, Dow Rallies; Bitcoin Sinks To $60,400: What's Driving Markets Monday?
June 24, 2024
Wall Street faces a continuation of last week’s trend during Monday’s morning trading, with semiconductor stocks selling off heavily and dragging down the tech sector, while the broader market remains...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
June 24, 2024
A 2024 coffee recall is in effect for products made by Snapchill LLC due to concerns of botulism from the FDA for hundreds of canned coffees.
Via
InvestorPlace
Exposures
Product Safety
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
June 24, 2024
The challenge for Alnylam now will be to find and diagnose patients with the condition known as ATTR-CM, which is considered rare.
Via
InvestorPlace
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
June 24, 2024
Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy. The trial showed significant reductions in mortality and...
Via
Benzinga
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
June 24, 2024
The companies are working on treatments for ATTR amyloidosis with cardiomyopathy.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.